IDEXX Laboratories Inc (IDXX) income statement
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$676.21−13.44 (-1.95%)
Close on Nov 20, 2026Market cap $53.27BP/E 47.6Yield –
IDEXX Laboratories Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 62.4%
- Operating margin
- 32.0%
- Net margin
- 25.0%
- Return on equity, FY2025
- 66.2%
Financial strength
- Current ratio
- 1.17
- Debt to equity
- 0.28
- Debt to assets
- 13.1%
- Cash to current liabilities
- 15.3%
Valuation
- P/E ratio
- 47.6
- Price to sales
- 11.70
- Price to book
- 33.04
- Dividend yield
- –
See a number that looks wrong?